SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059699
Filing Date
2024-05-14
Accepted
2024-05-14 16:43:05
Documents
64
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q avir-20240331.htm   iXBRL 10-Q 1815639
2 EX-31.1 avir-ex31_1.htm EX-31.1 13969
3 EX-31.2 avir-ex31_2.htm EX-31.2 14184
4 EX-32.1 avir-ex32_1.htm EX-32.1 9634
5 EX-32.2 avir-ex32_2.htm EX-32.2 8993
  Complete submission text file 0000950170-24-059699.txt   6557368

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT avir-20240331.xsd EX-101.SCH 909864
67 EXTRACTED XBRL INSTANCE DOCUMENT avir-20240331_htm.xml XML 946985
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39661 | Film No.: 24945203
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)